Carvedilol
Treatment for Alcoholic Cardiomyopathy
Typical Dosage: 3.125mg BID, titrated up to 25-50mg BID
Effectiveness
75%
Safety Score
70%
Clinical Trials
150
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanideâ ī¸
Methđ
CigarettesđŦ
Chemoâĸī¸
Alcoholđē
Morphineđ
Antibioticsđ
Tylenolđ
Exerciseđ
Waterđ§
70
DangerousModerateSafe
Treatment Details
Dosage Range
3.125mg BID, titrated up to 25-50mg BID
Time to Effect
8-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80
Monitoring:$300
Side Effect Mgmt:$50
Total Annual:$430
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$662
Comparison vs Placebo
Cost Difference
+$430/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$650
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$80/year
Potential OTC Price
$40/year
Estimated if OTC available
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWRequires Monitoring
YesNeeds lab work/checkups
Carvedilol Outcomes
for Alcoholic Cardiomyopathy
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Common Side Effects
Fatigue
+15%
Dizziness
+10%
Bradycardia
+5%
Hypotension
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov